- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Podcast: This Week in Managed Care—Updates on Nationwide Vaccine Availability and Other Health News
Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.
Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.
This week, the top managed care news included President Biden updating production timeline for nationwide vaccine availability; efforts by the National Quality Forum to measure telehealth quality and value; FDA approves first treatment for rare genetic metabolic pediatric disorder.
Listen above or through one of these podcast services:
Read more about the stories in this podcast:
How the National Quality Forum Plans to Measure Telehealth Quality, Value
FDA Approves First Treatment for Rare Genetic Metabolic Pediatric Disorder
Caring for the Whole Patient With Diabetes Drives ChristianaCare Pilot Success
Study Shows Higher Infection Risk in Patients With T1D in Primary, Secondary Care
November 22nd 2023Researchers concluded there is a clinically important increase in infection risk among patients with T1D in both primary care and hospital settings, and that guidelines must be developed to reflect this risk and encourage earlier treatment.
Read More
Managed Care Cast Presents: Opportunities for Adalimumab Biosimilars, Part 1
November 10th 2023In part 1 of this 2-part podcast, a panel of experts discusses the provider and payer considerations for transitioning patients to biosimilars, approaches to prescribing biosimilars over reference products, and more.
Listen
Study Reveals Racial Disparities in Immune Tolerance Induction Treatment for Hemophilia
November 14th 2023New research highlights racial disparities in hemophilia care, revealing that Black and Hispanic patients are significantly less likely to receive immune tolerance induction treatment compared with White patients, even after considering clinical factors.
Read More
